Immunoconjugates of antibodies with toxic agents are becoming a significant component of anticancer treatments. One ongoing challenge to the success of this approach is the exposure of healthy tissues to the cytotoxic agents employed. We propose that magnetic fluid hyperthermia, using pre-targeted antibody-iron oxide magnetic nanoparticles, can address this issue. In magnetic fluid hyperthermia an alternating magnetic field is applied to magnetic nanoparticles in target tissues causing localised heating and cell death. The externally employed magnetic field can be focused on the tumour deposit. The system has potential to provide potent and selective cancer-targeted hyperthermic therapy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Plastic, Reconstructive & Aesthetic Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2007 Published by Elsevier Inc.